Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Potential adverse effects and inferior efficacy in ARV treatment.

Graves D, Cocohoba J, Gruta C, Goldschmidt R.

J Natl Med Assoc. 2004 May;96(5):692-3; author reply 693. No abstract available.

2.

[Hepatotoxicity of coinfected patients].

Bessone F, Belloso W, Schroder T.

Acta Gastroenterol Latinoam. 2006 Jun;36 Suppl 1:S43-5; discussion S74-82. Spanish. No abstract available.

PMID:
16862858
3.

Actual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads.

Clay PG.

J Int Assoc Physicians AIDS Care (Chic). 2004 Apr-Jun;3(2):49-55.

PMID:
15346690
4.

[Current status and future issues of anti-HIV chemotherapy].

Matsushita S.

Uirusu. 2003 Dec;53(2):141-6. Review. Japanese. No abstract available.

5.

Elevated liver enzymes in HIV monoinfected patients on HIV therapy: what are the implications?

Ingiliz P, Benhamou Y.

J HIV Ther. 2009 Mar;14(1):3-7. No abstract available.

PMID:
19731558
6.

[HIV-infection].

Wasmuth JC, Rockstroh JK.

Dtsch Med Wochenschr. 2007 Mar 30;132(13):673-83; quiz 685-6. Review. German. No abstract available.

PMID:
17377882
7.

[Adverse effects of antiviral agents].

Moriuchi M, Moriuchi H.

Nihon Rinsho. 2007 Oct 28;65 Suppl 8:233-41. Review. Japanese. No abstract available.

PMID:
18074544
8.

The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection.

Huang HY, Daar ES, Sax PE, Young B, Cook P, Benson P, Cohen C, Scribner A, Hu H.

HIV Med. 2008 May;9(5):285-93. doi: 10.1111/j.1468-1293.2008.00561.x.

9.

New antiretroviral drugs and approaches to HIV treatment.

Paredes R, Clotet B.

AIDS. 2003;17 Suppl 4:S85-96. Review. No abstract available.

PMID:
15080184
10.

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.

Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group.

J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18.

12.

Why switch from protease inhibitors (PI) to non-nucleoside reverse transcriptase inhibitors (NNRTI)?

Pozniak AL.

HIV Med. 2000;1 Suppl 1:7-10. Review. No abstract available.

14.

HIV-associated lipodystrophy: impact of antiretroviral therapy.

Guaraldi G, Stentarelli C, Zona S, Santoro A.

Drugs. 2013 Sep;73(13):1431-50. doi: 10.1007/s40265-013-0108-1. Review.

PMID:
24002702
15.

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, Brinson C, Benson P, Dau L, Wang H, White K, Flaherty J, Fralich T, Guyer B, Piontkowsky D.

Clin Infect Dis. 2013 Jun;56(11):1637-45. doi: 10.1093/cid/cis1203. Epub 2013 Jan 29. Erratum in: Clin Infect Dis. 2013 Sep;57(5):779.

16.

Cardiovascular risks of antiretroviral therapy.

Stein JH.

N Engl J Med. 2007 Apr 26;356(17):1773-5. No abstract available.

PMID:
17460232
17.

Once-daily therapies.

Carey D.

J HIV Ther. 2003 Feb;8(1):7-11. Review.

PMID:
12840708
18.

[Antiretrovirals].

Teruya K.

Nihon Rinsho. 2007 Feb 28;65 Suppl 2 Pt. 1:384-9. Review. Japanese. No abstract available.

PMID:
17455650
19.

Notes and quotes. New drugs give hint of promise in treating HIV/AIDS.

Susman E.

AIDS. 2001 Jul 6;15(10):N11-2. No abstract available.

PMID:
11426089
20.

The LATTE study: a provocative brew.

Boyd MA, Cooper DA.

Lancet Infect Dis. 2015 Oct;15(10):1116-7. doi: 10.1016/S1473-3099(15)00224-8. Epub 2015 Jul 19. No abstract available.

PMID:
26201302
Items per page

Supplemental Content

Write to the Help Desk